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1. INTRODUCTION
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1.1. Overview oncofertility  
 
Today, patients can look forward to life after malignant diseases such as cancer, yet 
many may face the possibility of infertility as a result of the disease itself or its lifesaving 
treatments (1). Oncofertility has emerged as a new branch of medicine, with the task of 
developing a safe and effective method of preserving fertility in men and women. The name 
was first used by Teresa K. Woodruff in 2006 and since then oncofertility developed as a new 
discipline of gynecology and obstetrics (2). The need for further investment in this branch has 
two major reasons. First concern is the increasing incidence of malignant diseases in children 
and young adults. Secondly, advances in cancer diagnosis and the introduction of new cancer 
treatments have dramatically improved the chance of survival, allowing patients and 
practitioners to think beyond the cure to future quality of life. Unfortunately, to treat these 
malignant diseases, aggressive therapy is necessary, which causes a marked reduction in 
reproductive potential. 
In 2006, it was estimated that around 750 000 young women only in the USA had to 
undergo cancer treatment during their childbearing age. Among these female cancer survivors 
who were under the age of 40 at diagnosis, the chance of getting pregnant was 20% lower in 
those diagnosed as children, and 50% lower in those diagnosed as young adults, compared to 
female siblings without cancer. Those numbers seen in a global dimension, represent a 
tremendous unmet need regarding the level of infertility and its extent on survivors’ quality of 
life (3). 
Also, the number of young patients whose reproductive futures may be affected by 
cancer treatment or the cancer itself is not small. In 2016 approximately 9 million people were 
diagnosed with malignant neoplasms worldwide, and around 1,1 million diagnoses were made 
in patients younger than 45 years of age (4), a time when many may be thinking about or 
actively building their families. Especially these patients need reproductive consult at the time 
of diagnosis to address options for preserving fertility before cancer treatment begins (3). 
Most impressive survival statistics can be found in children diagnosed with cancer. Childhood 
cancer patients (age 0–14 years) have an average 85% chance of survival. For this reason, 
addressing the late effects associated with cancer treatment in these prepubertal patients, such 
as reproductive and endocrine issues, has also taken an important part in today’s medicine (3). 
The office for National Statistics in Great Britain found out that leukemia, non-
Hodgkin’s lymphoma and brain were the most common cancers registered in young boys (0 to 
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14 years old). In young girls, the kidney was the most common site. These cancers accounted 
for over half of the 1,359 cancer cases registered in children. 
For males aged 15 to 49, testicular, skin melanoma, and bowel cancer were the 3 most common 
cancer registrations. For females the same age the most prevalent cancer sites were breast, skin 
melanoma and cervical cancer. 
In older patients, being 50+ respectively, prostate, breast, lung, and colorectal cancer 
were the most common cancer cases registered (5). 
 
1.2. Gonad toxicity  
It was shown that chemotherapy and radiotherapy have adverse effects on the organs of 
men and women as they can lead to complete dysfunction of the testis or ovaries respectively, 
resulting in infertility. Infertility is defined as the inability to conceive within a period of 12 
months of unprotected sex. Gonad toxicity can also cause the advent of premature menopause 
(before the age of 40) due to premature ovarian failure (POF) and prevent puberty from 
proceeding normally (3). 
 
1.3. Radiotherapy  
Ionizing radiation causes direct damage to deoxyribonucleic acid (DNA) leading to cell 
damage and death. Radiosensitivity is highest in cells which are highly mitotic or 
undifferentiated. For this reason, the gonads are considered highly radiosensitive and are 
therefore very susceptible for radiotherapy. At the time of birth, the ovaries contain a finite 
number of follicles, which accounts for about 2 million. That number continues to decrease 
until menopause. Destroying all follicles will cause irreversible infertility. The schedule of the 
delivered irradiation (total dose, number of fractions, and duration) is an important determinant 
of the radiobiological effect on the tissues involved and varies among different tissues and 
organs. Irradiation to the central nervous system may affect the timing of the onset of puberty, 
result in hyperprolactinemia, or cause gonadotropin deficiency if the hypothalamic-pituitary 
axis is involved in the radiation field (6). Direct irradiation to the testis will, in lower doses, 
affect the germinal epithelium. Doses of irradiation greater than 0.35 Gy will lead to a 
temporary azoospermia. The time until normal spermatogenesis is reinstalled, increases with 
larger doses. However, with doses more than 2 Gy the absence of sperm may be permanent. At 
very high radiation doses (> 15 Gy), Leydig cell function will also be affected. In addition to 
radiation dose, the damage potential of the testis is dependent on the age at irradiation and the 
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pubertal status of the male. In females, the vulnerability of the ovary to irradiation varies with 
age as well as dose, and separation of ovarian dysfunction into hormonal and fertility effects is 
not clear-cut. An ovarian dose of 4 Gy may cause a 30% incidence of sterility in young women, 
but 100% sterility in women over 40 years of age. Pelvic irradiation may also have a significant 
effect on the uterus, with restricted growth in the prepubertal girl, and failure of uterine 
expansion during pregnancy leading to miscarriages and premature labor (7). 
 
1.4. Chemotherapy  
Chemotherapy damages the ovaries in three ways. We can distinguish between direct 
damage of the ovary, ovarian damage as a result of vascular damage and damage at the cell 
level (oxidative stress) (6). Direct damage causes impairment of follicular maturation or direct 
toxicity on quiescent primordial follicles or the combination of two, resulting in an overall 
reduction of oocytes and a temporary loss of menstruation, the so-called burn-out effect. The 
clinical impact of chemotherapeutic drugs on the ovary is variable, ranging from no effect to 
complete ovarian atrophy. However, the degree of damage is usually dependent upon the type 
of the chemotherapeutic agent used, dose given, age of the patient and the baseline ovarian 
reserve. The prepubertal ovary is less susceptible to the sequelae of chemotherapeutic agents 
while older women, having a lower ovarian reserve, are more susceptible to premature ovarian 
failure (POF) (7). 
In women who are 20 years old, it took about 20,400 mg cyclophosphamide for the 
occurrence of amenorrhea, in women 30 years old, 9300 mg, and for women of 40 years only 
5200 mg of cyclophosphamide (8). The groups of chemotherapeutic agents can differ in the 
mode of action, as demonstrated in Figure 1, and consequently have adverse effects on the 
reproductive system. Alkylating agents have an extremely damaging effect and are responsible 
for the highest age-adjusted odds ratio of ovarian failure rates.  
Platinum-based compounds such as cisplatin cause DNA damage. They carry a medium risk of 
amenorrhea. Anthracycline antibiotics such as doxorubicin (DXR) induce oxidative stress. The 
amenorrhea and fertility risk are medium to low with this group of drugs (9). 
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Figure 1. Cytotoxic drugs and their action on the ovary 
 
Reprinted from: Mahajan N. Fertility preservation in female cancer patients: An 
overview. Journal of Human Reproductive Sciences. 2015;8(1):3-13. 
Fibrosis of blood vessels due to toxic agents add to the ovarian damage. Ben-Aharon et 
al. followed 20 women during and after chemotherapy with a focus on vascular damage. They 
found out that ovarian toxicity manifested by decreased ovarian blood flow accompanied by a 
reduction in ovarian size and diminished post-treatment anti-Müllerian hormone (AMH) levels 
(10). 
The endogenous free oxygen radicals have proved to be crucial factors in apoptosis of 
antral follicles in response to ionizing radiation and toxins, reducing fertility in women who 
received chemotherapy (11).  
The normalization of the menstrual cycle after the treatment ensures normal 
reproductive capacity. It is important to note that the patients who received gonadotoxic 
treatments usually enter menopause earlier than healthy women (12). There is a risk of post 
chemotherapy loss of ovarian function several years after the treatment of malignant disease 
(10).  
Chemotherapeutic agents also have detrimental effects on spermatogenesis, causing 
temporary, long-term, or permanent gonadal toxicity in men. The relatively long time span of 
loss of functional sperm production, is based on the fact that the rapidly dividing differentiating 
spermatogonia are much more sensitive to killing than later stage germ cells, and that the 
kinetics of spermatogenesis is fixed and unchanged after cytotoxic treatments. Thus, the 
surviving later stage germ cells progress along their differentiation pathway but are not replaced 
by new cells that would have been derived from the differentiating spermatogonia that have 
been destructed. Hence there is a progressive loss of the more mature differentiating cells in a 
process called maturation depletion.  
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Alkylating drugs are the most potent at producing long-term azoospermia. In male 
patients, who are being treated for testicular cancer a common choice of chemotherapy is either 
based on cisplatin or carboplatin. Lampe et al. analyzed data concerning 170 patients with 
testicular germ cell cancers who underwent treatment with either cisplatin- or carboplatin-based 
chemotherapy. Forty of these men (24%) were azoospermic before the treatment, and a further 
41 (24%) was being found to be oligospermic. A median of 30 months after the completion of 
chemotherapy, only 64% of those patients who had a normal sperm count before therapy 
remained normospermic, while 54 (32%) of the total cohort were azoospermic and 43 (25%) 
were oligospermic (13). The probability of recovery to normospermia appeared to be higher for 
those men with a normal pretreatment sperm count, in those who received carboplatin- rather 
than cisplatin-based therapy, and in those treated with fewer than five cycles of chemotherapy. 
Recovery of the patients lasted for more than 2 years, with the calculated chance of 
spermatogenesis at 2 years being 48% and at 5 years 80% (14). 
 
1.5. Process of cryopreservation 
Cryopreservation (CP) is the freezing of gametes, embryos and testicular tissues to 
maintain their viability over time. The first step is cooling the temperature of 37 ° C to a 
temperature of -196 ° C. Second step is to re-thaw the sample to a temperature of 37 ° C after a 
certain period, meaning when the patient wishes to use the sample (8). The biggest obstacle 
during this process is to remove the water successfully from the cells without causing their 
death. Freezing water increases its volume and can lead to rupture of the cell membranes and 
damaged organelles within the cell. Therefore, before freezing the water needs to be replaced 
by a cryoprotectant medium. There are penetrating and non-penetrating cryoprotectants. 
Penetrating cryoprotectants cause membrane lipid and protein rearrangement, resulting in 
increased membrane fluidity, greater dehydration at lower temperatures, reduced intracellular 
ice formation, and increased survival to cryopreservation. Additionally, penetrating 
cryoprotectants are solvents that dissolve sugars and salts in the cryopreservation medium. A 
non-penetrating cryoprotectant does not cross plasma membrane and only acts extracellularly. 
Therefore, non-penetrating cryoprotectant may alter the plasma membrane, or act as a solute, 
lowering the freezing temperature of the medium and decreasing the extracellular ice formation 
(15). There are two methods to do cryopreservation, slow freezing and vitrification. Slow 
freezing is the conventional method in which the temperature drops slowly, by 0.3 ° C per 
minute to the desired temperature of -32 ° C to ensure the tissue is dehydrated before 
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intracellular ice formation occurs. After that, the sample is transferred to the liquid nitrogen 
temperature of -196 ° C. Whereas in conventional cryopreservation the concentration of the 
cryoprotectant is low and the cooling rate is very slow to avoid ice crystallization, vitrification 
is an ultra-rapid cooling technique that requires a high concentration of cryoprotectant (16). 
Figure 2 compares the survival rates of oocytes in 5 different studies, using slow 
freezing or vitrification: 
 
Figure 2. A summary of randomized controlled trials reporting the egg survival rate of slow 
freezing and vitrification 
Reprinted from: http://www.smartfertilitychoices.com/your-ultimate-guide-to-egg-freezing/ 
1.6. Oncofertility procedures  
1.6.1. Cryopreservation of embryos and oocytes 
1.6.1.1. Controlled ovarian stimulation 
Cryopreservation of embryos and cryopreservation of oocytes are both methods of 
preserving fertility in women. It is considered as the golden standard for patients threatened 
with the loss of ovarian function due to gonadotoxic therapy (17). The common step at the 
beginning of both methods is controlled ovarian stimulation (COS). Before treatment starts, the 
patient should undergo thorough screening and check-up. In addition to determining the type 
of tumor and its stage, it is of great significance to estimate the time remaining until 
commencement of cancer therapy. Also, the patient’s ovarian reserve should be calculated to 
identify whether the method is fitting for that specific patient. It is usually determined by the 
number of antral follicles, AMH levels and follicle stimulating hormone (FSH) (18). 
Nowadays, we use AMH levels and the antral follicular count to predict the success of in vitro 
fertilization (IVF). AMH markers are considered more accurate because its levels do not change 
during the cycle but can serve as a marker at any time (19). Controlled ovarian stimulation is a 
method in which exogenous hormones are administered to achieve synchronized growth and 
development of several follicles at once. This ensures a greater number of released mature 
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oocyte per cycle. Controlled ovarian stimulation comprises three main elements: Exogenous 
gonadotropins to stimulate multi-follicular development, cotreatment with either gonadotropin-
releasing hormone (GnRH) agonist or antagonists, to suppress pituitary function and prevent 
premature ovulation by a luteinizing hormone (LH) surge, and finally triggering oocyte 
maturation 36 to 38 hours prior to oocyte retrieval.   
GnRH agonists or antagonists have been used in a number of different protocols. In the 
so-called 'long protocol', the GnRH agonist is started at least two weeks before stimulation and 
continued up until oocyte maturation is achieved. Alternatively, a 'short protocol' is used in 
which the GnRH agonist is commenced simultaneously with stimulation and continued up until 
the day of oocyte maturation trigger. Yet another option is the use of GnRH antagonists. This 
involves a shorter duration of use compared with the agonist 'long protocol' and is started a few 
days after initiation of stimulation, continuing up until administration of the drug triggering 
oocyte maturation. The trigger is used at the end of the stimulation phase of an IVF cycle and 
mimics the natural endogenous LH surge in order to initiate the process of ovulation. Two drugs 
are currently used: human chorionic gonadotropin (hCG), which is the most common drug, or 
GnRH agonist in an antagonist protocol (17). 
In today’s protocols exogenous gonadotropins are administered daily for 9-14 days, 
starting in the early follicular phase. As already mentioned before, the second step would be to 
prevent the premature ovulation by administering GnRH agonists during the luteal phase. In 
addition to GnRH agonists, the use of GnRH antagonists to prevent ovulation has been 
evaluated. Antagonists are administered when the leading follicle diameter is 12-14 mm, which 
is usually by the sixth day of stimulation. The use of a GnRH antagonist shortens the process 
of ovarian stimulation markedly by 14 days which is a great advantage compared to GnRH 
agonists (20). The different proceedings are illustrated in Figure 3: 
 
Figure 3. Suppression of spontaneous ovulation 
Reprinted from: http://www.motherhoodconsultancy.com/controlled-ovarian-hyperstimulation/ 
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In the GnRH agonist protocol, hCG is applied intramuscularly once the leading follicle 
has reached an appropriate size. Aspiration of oocytes is then performed 36 to 38 hours after 
the time of administration of hCG (21).  
In addition to the conventional protocol, a non-conventional protocol has been 
developed. Unlike the standard protocol, in which patients must be in early follicular phase to 
start stimulation, patients can also begin in late follicular or luteal phase of the cycle. This is 
also called random-start COS and has been reported as an alternative method for cancer 
patients, with the benefit of a shortened interval from presentation to retrieval and thus to cancer 
treatment. The conventional approach requires approximately 2 weeks of ovulation induction 
from the beginning of the menstrual cycle. This process could entail a delay by up to 6 weeks 
from starting cancer treatment, depending on the phase of the menstrual cycle during which the 
patient is referred (22). 
Baerwald et al. followed the ovaries of 50 healthy women in their reproductive age 
every day by transvaginal ultrasound over the period of one interovulatory interval (IOI). They 
found out that women exhibit a follicular wave phenomenon, in which follicles not only grow 
during the follicular phase of the menstrual cycle but show major and minor waves of growth 
ranging from two to three ovarian follicular waves during one interval. This means that the 
selection of a dominant follicle for preferential growth and development to an ostensibly 
ovulatory diameter can occur at more than one time during the menstrual cycle. Only the final 
wave of each cycle was ovulatory; all preceding waves were anovulatory (23).  This opens two 
additional starting points for controlled ovarian stimulation in patients who might not be able 
to wait 2-6 weeks: the late follicular phase and/or luteal phase. The first option is to start the 
stimulation after a spontaneous LH surge. The second option is after ovulation, induced by 
administration of a GnRH agonist or hCG. In the random start-protocol, like in the conventional 
one, GnRH antagonists are used later in the cycle, or if the diameter of the follicles is larger 
than 12 mm. The task of GnRH antagonists is the prevention of a LH surge, and the application 
is continued until ovulation induction with GnRH agonists or hCG is started. The only 
exception is its use in the late follicular phase, if the diameter of follicles reached 12 mm before 
the spontaneous LH surge. In this case, administration of a GnRH antagonist starts immediately 
and continues until ovulation induction (24). Jee Hyun Kim et al. evaluated the efficacy of 
random-start controlled ovarian stimulation (COS) in cancer patients for emergency fertility 
preservation. In this retrospective comparative study they included 22 patients diagnosed with 
cancer and 44 infertile women undergoing conventional in vitro fertilization (IVF). In cancer 
patients, ovarian stimulation was started on the day of referral, irrespective of their menstrual 
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cycle date. The control group was selected by age matching among women undergoing 
conventional IVF. COS outcomes were compared between groups. The number of total and 
mature oocytes retrieved, and the oocyte maturity rate were higher in the random-start group 
than in the conventional-start group. However, ovarian stimulation took more time in the 
random-start group (11.4 vs. 10.3 days, p = 0.004). The results confirm the feasibility and 
effectiveness of random-start COS in cancer patients and proves that progesterone levels in the 
luteal phase and the presence of the corpus luteum have no negative effects on the development 
of oocytes (25). It is therefore of utmost importance to familiarize cancer patients with the 
possibility of preserving fertility, about its process, and to point out that it does not significantly 
delay therapy. 
In oncology, hormone-sensitive tumors make up an exceptional group. The most 
common one that occurs in women is breast cancer, followed by endometrial cancer. The 
percentage of breast tumors that are sensitive to hormones is up to 60%. To identify those 
patients is exceptionally important for their further treatment, as hormones binding to these 
receptors enhance tumor cell proliferation. Stimulation of the ovaries increase the number of 
antral follicles. This leads to an increased number and proliferation of granulosa cells (8). These 
cells contain the enzyme aromatase, and its membrane the receptors for FSH. FSH binding to 
the receptors, activate the enzyme aromatase, and thus converts androstenedione to estrone and 
testosterone to estradiol. In the normal menstrual cycle, the peak concentration of estradiol is 
around 300 pg/mL, in COS, however, values of 3000 pg/mL can be reached, arising concerns 
that the stimulation of ovulation would further encourage tumor growth and increase 
mortality. Therefore, alternative and potentially safer protocols have been introduced for 
fertility preservation in estrogen-sensitive cancer patients, including natural-cycle IVF (without 
ovarian stimulation), stimulation protocols with tamoxifen alone or combined with 
gonadotropins, and stimulation protocols with aromatase inhibitors to reduce the estrogen 
production (24). 
Natural-cycle IVF gives only one or two oocytes or embryos per cycle and has a high 
rate of cycle cancellation. Therefore, this technique can be considered as likely ineffective and 
is not recommended, especially when a chemotherapy treatment is pending, and the patient does 
not have a chance for a second cycle of IVF treatment (24). 
Tamoxifen, a nonsteroidal triphenylethylene compound, has an antiestrogenic action on 
breast tissue. It inhibits the growth of breast tumors by competitive antagonism of estrogen at 
its receptor site. It is accepted as the first-line drug in hormonal prevention and treatment of 
estrogen receptor–positive breast cancer. Tamoxifen, besides its effect in the breast, also has an 
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antagonist action in the estrogen receptors in the central nervous system. The selective 
antagonist action of tamoxifen intervenes with the negative feedback of estrogen on the 
hypothalamic-pituitary axis, resulting in an increase in GnRH secretion from the hypothalamus 
and a subsequent release of FSH. Tamoxifen can be used for COS alone starting on day 2–5 of 
the menstrual cycle in doses of 20–60 mg/d, or in combination with gonadotropins. Even though 
peak estradiol levels in ovarian stimulation with tamoxifen are not altered, owing to its 
antiestrogenic effect on breast tissue, it should preferably used in estrogen receptor–positive 
breast cancer patients. In a study of Oktay et al., ovarian stimulation with the use of tamoxifen 
for fertility preservation in cancer patients was shown to increase the mature oocyte and embryo 
yield compared with natural-cycle IVF (1.6 vs. 0.7 and 1.6 vs. 0.6, respectively) and reduce 
cycle cancellations. Combined protocol with tamoxifen and gonadotropins further increased the 
number of cryopreserved oocytes and embryos (5.1 vs. 1.5 and 3.8 vs. 1.3, respectively) (26). 
Stimulation protocols with aromatase inhibitors, such as letrozole, markedly suppress 
plasma estrogen levels by competitively inhibiting the activity of the aromatase enzyme. 
Aromatase is a cytochrome P450 enzyme complex that catalyzes the conversion of 
androstenedione and testosterone to their respective estrogenic products estrone and estradiol 
(27). Aromatase inhibitors significantly reduce the risk of recurrence in postmenopausal women 
with hormone receptor–positive breast cancer owing to profound estrogen deprivation (28). 
Centrally, aromatase inhibitors rid the hypothalamic-pituitary axis of the estrogenic negative 
feedback, increase the secretion of FSH by the pituitary gland, stimulate follicle growth, and 
therefore make it suitable for ovulation induction (29). In patients with estrogen-sensitive 
cancers, the main advantage of adding daily letrozole to gonadotropins in ovarian stimulation 
protocols is to decrease serum estradiol levels to be closer to that observed in natural cycles 
without affecting oocyte or embryo yield (30,31). Stimulation protocols using letrozole 
alongside with gonadotropins are currently preferred over tamoxifen protocols as treatment 
with letrozole results in a higher number of oocytes obtained and fertilized when compared to 
tamoxifen protocols (26). A study of Oktay et al. compares the efficacy of the letrozole plus 
gonadotropin protocol in breast cancer patients and the standard IVF protocol in age-matched 
noncancer patients with tubal-factor infertility. The breast cancer patients started to receive 
letrozole (5 mg/d) on menstrual cycle day 2 or 3, and FSH (150–300 IU/d) was added 2 days 
later. All medications were discontinued on the day of hCG trigger, and letrozole was reinitiated 
after oocyte retrieval and continued until estradiol levels fell to <50 pg/mL (31). This protocol 
resulted in similar number of total oocytes retrieved and length of ovarian stimulation compared 
with standard IVF protocol (31). Peak estradiol levels were shown to be significantly lower 
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in the breast cancer patients receiving letrozole plus gonadotropin compared with the standard 
IVF group (483 ± 278.9 pg/mL vs. 1,464.6 ± 644.9 pg/mL). Other studies assessed the effect 
of letrozole on oocyte maturity and competence. They demonstrated that the addition of 
letrozole did not change numbers of mature oocytes retrieved and fertilization rates (31,32). 
Azim et al. further found out that the short-term follow-up of breast cancer patients, who had 
undergone ovarian stimulation with letrozole plus gonadotropins for fertility preservation, has 
not revealed a raise in the risk of breast cancer recurrence (33). In addition, COS with letrozole 
in combination with gonadotropins has been safely used for embryo cryopreservation in 
endometrial cancer patients (34). Discontinuation of letrozole can either be at menses or with 
initiation of chemotherapy. In contrast, anastrozole, another third-generation aromatase 
inhibitor, failed to adequately suppress estradiol levels during COS, despite gradually 
increasing the dose to a maximum, and therefore its use is not recommended in fertility 
preservation cycles (35). 
In summary, COS with letrozole plus gonadotropins in patients with estrogen-sensitive cancers 
undergoing fertility preservation is safe, well-tolerated, and yields similar number of oocytes 
and embryos compared to standard protocols while minimizing the risk of high estrogen 
exposure and not increasing the risk of recurrence of cancer in the short term. 
Carriers of the BRCA gene make up another group of special cancer patients in need of 
an adjusted therapy. BRCA genes play an essential role in double-strand DNA break repair, and 
their mutations are associated with an increased risk of breast and ovarian cancers. Therefore, 
in patients with BRCA mutations, oocytes may be more prone to DNA damage, clinically 
manifesting as diminished ovarian reserve or earlier menopause. In BRCA mutation–positive 
breast cancer patients, Oktay et al. found out that a low response to ovarian stimulation occurred 
more frequently than in patients without BRCA mutations (33.3% vs. 3.3%) or in breast cancer 
patients not tested for their BRCA status (2.9%). Interestingly, all BRCA mutation–positive 
patients with a low response to ovarian stimulation and requiring higher doses of gonadotropins 
for their stimulation had BRCA-1 mutations. A low response was not encountered in women 
who were positive for only BRCA-2 (36). 
Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of ovarian 
stimulation and can be associated with intravascular depletion, ascites, liver dysfunction, 
pulmonary edema, electrolyte imbalance, and thromboembolic events. Although OHSS is often 
self-limited with spontaneous resolution within a few days, severe disease can require 
hospitalization and intensive care. The impact can be especially profound in cancer patients 
because it may result in a delay or complications of imminent cancer therapy (37). 
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Triggering the final oocyte maturation with hCG carries the risk of inducing OHSS (38). GnRH 
agonist also induces this final oocyte maturation by promoting the release of endogenous 
gonadotropin stores from the pituitary gland, as long as its gonadotropin receptors are not down-
regulated. It can therefore be used as an alternative to hCG (38), which dramatically reduces 
the risk of OHSS, owing to the short half-life of a GnRH agonist–induced endogenous LH surge 
(39). In a study of Oktay et al., comparing GnRH agonist and hCG as the trigger for oocyte 
maturation in fertility preservation cycles, GnRH agonist trigger resulted in at least similar 
numbers of mature oocytes and cryopreserved embryos compared to hCG (40). In addition, 
although hCG potentiates the endogenous production of estrogen during the luteal phase owing 
to its longer half-life, GnRH agonist–induced endogenous LH may result in lower estrogen 
production, which may be an advantage for patients with estrogen-sensitive cancers (38). 
However, the use of GnRH agonists may result in a failed induction of ovulation (41). The 
expected risk lies between 1.4 and 3.5% (42). This can be prevented by either higher doses of 
GnRH agonists or hCG can be added to induce ovulation (41). 
 
1.6.1.2. Cryopreservation of embryos 
The ability to cryopreserve, thaw, and accomplish pregnancies with supernumerary 
preimplantation embryos has become a valuable tool in fertility treatment. In a routine IVF 
practice, 60 % of stimulated IVF cycles may achieve surplus embryos suitable for 
cryopreservation (43). There are two methods of cryopreservation: slow-rate freezing and 
vitrification. Vitrification is now considered superior to the traditional slow-rate freezing. 
Survival rate of cleavage stage embryos was significantly higher after vitrification as compared 
with slow freezing. Vitrifying 1600 embryos, Kuleshova and Lopata reported a 84% survival 
rate with a 51% pregnancy rate (44). Desai et al performed a study of vitrification on human 
embryos at 6–8 cell-stages. The post-warming survival rate was 85%, the implantation rate was 
19.9% and the clinical pregnancy rate was 44.2% . Also post thawing survival rate of vitrified 
blastocysts was significantly higher compared with that observed with slow freezing (45). 
Liebermann and Tucker had reported in their study 96.5%, 30.6%, and 88.6% for survival, 
implantation, and pregnancy rates respectively (46).  
Besides, studies of Riggs et al. have demonstrated no correlation between embryo 
storage duration and the live birth rate (47), which is soothing for oncology patients, given they 
often have to delay pregnancy to complete therapy and due to concerns over cancer recurrence 
(48). 
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Cardozo et al. compared in-vitro fertilization (IVF) outcomes of cancer patients who underwent 
oocyte retrieval and embryo cryopreservation prior to gonadotoxic therapy to those of age and 
time-matched controls with tubal factor infertility. Out of sixty-three cancer patients, 21 
returned for frozen embryo transfer. In the control group of 122 age-matched patients, 23 
returned for frozen embryo transfer. No difference was seen between cancer patients and 
controls with respect to number of oocytes retrieved and number of embryos obtained. The 
pregnancy rate per transfer for cancer patients compared to controls was 37 vs. 43 % 
respectively, and the live birth rate per transfer was 30 vs. 32 % respectively (49). These results 
clearly show the efficacy and utility of this method for cancer patients. 
Although considered the golden standard, it shows some limitations. One would be the 
necessity for COS and the time it takes to perform it, which some cancer patients might not 
have. There is also the need for a male partner, which can produce viable sperm. Finally, the 
storage of embryos has elicited religious and ethical issues, as well as concerns regarding cost-
effectiveness, resulting from high disposal and non-usage of embryos (50). 
 
1.6.1.3. Cryopreservation of oocytes  
Mature oocyte cryopreservation is a currently available method of fertility preservation 
in women of reproductive age. Even though it efficacies remains low compared to embryo CP, 
it should be preferred when the latter is prohibited by law, avoided for ethical or religious issues 
and in single women refusing sperm donation (43). It also helps to overcome problems, for 
example when the husband is unable to produce a viable sperm sample or when spermatozoa 
cannot be found in the testis in case of non-obstructive azoospermia. Moreover, with the help 
of oocyte CP, not only women but also young female cancer patients could store their gametes 
before undergoing gonadotoxic therapy. In all these cases, banking mature oocytes is a 
reasonable fertility-preserving alternative. In the past 10 years, methods of vitrification have 
been refined to optimize oocyte survival after cryopreservation (51-54). Both clinical trials and 
observational studies have compared reproductive outcomes after IVF and intracytoplasmic 
sperm injection (ICSI) with cryopreserved oocytes to IVF and ICSI with fresh oocytes. 
Outcomes of four published randomized controlled trials demonstrated that fresh and frozen 
oocytes yield similar pregnancy rates in IVF cycles, supporting the use of these technologies in 
selected patients aged 35 years and younger (55-58). In the two studies conducted in infertile 
couples, implantation rates ranged between 17% and 41% and clinical pregnancy rates per 
transfer ranged from 36% to 65% (56, 58). These data, and data from a recent meta-analysis 
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(59) suggest that specific outcomes of IVF and ICSI (fertilization and pregnancy rates) are 
similar between fresh oocytes and vitrified oocytes. An important clinical predictor of outcomes 
in the observational studies of oocyte cryopreservation and IVF is the age of the oocyte when 
frozen or vitrified (60-63). Several studies have displayed that a more advanced age of the 
oocyte, when frozen or vitrified, reduces the odds of success when used for IVF or ICSI.  
Oktay et al. analyzed the efficacy of oocyte cryopreservation in cancer patients, by slow-
freezing and vitrification methods using a meta-analysis. They reported live birth rates per 
oocyte thawed of 3.4 % for slow freezing and 6.6 % for vitrification (64). These results suggest 
that acceptable live births after oocyte cryopreservation can occur in cancer patients. However, 
it is important to note that most retrospective studies on successful oocyte cryopreservation in 
cancer patients have been case reports. Therefore, it is possible that results that did show an 
unsuccessful pregnancy were excluded. Due to this, it is still difficult to predict the possibilities 
of having a live birth. Further long-term follow-up studies on cancer patients would more 
accurately determine the efficiency of oocyte cryopreservation. 
Today, oocyte cryopreservation, with appropriate counseling, is recommended for patients 
facing infertility due to chemotherapy or other gonadotoxic therapies, and who do not wish or 
cannot perform embryo CP. Unfortunately, despite the increasing use of this strategy, data are 
still lacking about the efficacy and safety of the procedure in female cancer patients. Also the 
age of the oocyte when vitrified has shown to play a major role in a successful pregnancy, and 
this method is therefore more recommendable for younger patients. 
 
1.6.2. Ovarian tissue freezing 
Ovarian tissue cryopreservation is still an experimental, but rapidly progressing 
technique (64). For ovarian tissue cryopreservation, ovarian tissue is obtained laparoscopically 
and cut into cortical strips which contain many primordial follicles. The tissue is then 
cryopreserved either by slow freezing or vitrification (65). Ovarian tissue can be drawn from 
any female patient irrespective of their age, while mature oocytes required for embryo or oocyte 
cryopreservation can be harvested only from postpubertal women. Ovarian tissue 
cryopreservation can furthermore be conducted within a few days because it is COS-
independent, while COS-dependent embryo or oocyte cryopreservation requires at least two 
weeks, no matter the protocol. Moreover, ovarian tissue cryopreservation comprises the 
possibility of being combined with embryo or oocyte cryopreservation (65). Ovarian tissue 
cryopreservation followed directly by COS and oocyte retrieval did not impair the number or 
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quality of the retrieved oocytes in cancer patients, as shown in a study of Dolman et al. (66). 
This combination may increase fertility preservation potential. When a patient wants to avail 
her cryopreserved ovarian tissues, they are thawed and transplanted. The most common place 
is in the pelvic cavity, either on the ovarian medulla or inside a peritoneal window (65,67,68). 
It has been shown that after transplantation of ovarian tissue in the pelvic cavity, ovarian 
endocrine activity is restored in more than 95% of cases (65, 69). As of the beginning of 2018, 
more than 130 live births after transplantation of ovarian tissue, cryopreserved either for 
oncologic or non-oncologic reasons, has been reported (69). A pregnancy rate after 
transplantation of ovarian tissue is not established since the number of transplantations 
performed worldwide is not known. However, a pregnancy rate and live birth rate are estimated, 
based on the results of several case series as 30–40% and 25–35%, respectively (65, 70–73). 
Pregnancies after ovarian tissue preservation resulted either from natural conception or from in 
vitro fertilization (74). The biggest concern regarding transplantation of cryopreserved ovarian 
tissue for oncologic reasons is the risk of reintroducing malignant cells contaminating the 
ovarian tissue, which is called minimal residual disease (MRD). The relative MRD risk for most 
types of cancer is still unknown, but the risk of MRD is considered to be high in leukemia 
patients (75, 76), moderate for gastrointestinal cancer, and low for breast cancer, sarcomas of 
the bone and connective tissue, Hodgkin’s and non-Hodgkin’s lymphoma (77). In addition, the 
methods to evaluate MRD in ovarian tissue is not established. Accordingly, ovarian tissue 
cryopreservation and transplantation is not recommended for leukemia patients at present (78).  
Ovarian tissue freezing is indicated in selected patients scheduled for treatments with a high 
risk of premature ovarian failure. This procedure can also be used in patients who are concerned 
and do not wish to undergo COS, or women with difficulties to undergo vaginal ultrasound 
examination. Furthermore, the technique can be proposed in patients who cannot delay the 
initiation of anticancer treatments (e.g. women diagnosed with an aggressive form of early 
breast cancer at a more advanced stage). Finally, it should be noted that, this is the only available 
option in prepubertal girls who are candidates for gonadotoxic treatments (79). 
 
1.6.3. GnRH agonists  
Administration of GnRH agonist has been considered a pharmacologic protection of the 
ovary during chemotherapy. The proposed mechanisms of action include hypogonadotropism-
induced ovarian quiescence and reduction of ovarian blood flow. Although GnRH agonist may 
have some medical benefits such as prevention of menorrhagia induced by thrombocytopenia 
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following chemotherapy, there is insufficient evidence regarding the effectiveness of GnRH 
agonist in fertility preservation (78). Several papers with conflicting results have continued to 
be published (80-82), but to confirm the protective effect of GnRH agonist, it would be 
necessary to show that administration of GnRH agonist is effective not only in the recovery of 
menses, but also in achieving pregnancy. Moreover, a recent report by Demeestere et al., of a 
prospective randomized trial, with a median follow-up time of five years, showed that the 
GnRH agonist is not efficient in preventing chemotherapy-induced premature ovarian failure 
and has no influence on the future pregnancy rate (83). Therefore, temporary ovarian 
suppression with GnRH agonists during chemotherapy should not be considered as an 
alternative to embryo/oocyte cryopreservation or ovarian tissue freezing (84). In patients 
interested in fertility preservation, embryo and oocyte cryopreservation remain the first options 
to be proposed (85,86). Temporary ovarian suppression with GnRH agonists during 
chemotherapy should be considered in patients interested in ovarian function preservation only 
(e.g. in women concerned about the risk of developing treatment-induced premature ovarian 
failure but not interested in having a subsequent pregnancy). It is also an option for those 
interested in fertility preservation after cryopreservation procedures or when all other 
techniques are contraindicated or not available. 
 
1.6.4. Cryopreservation of semen  
Semen cryopreservation is a simple procedure that holds foremost importance for men 
who have cancer and who wish to preserve their reproductive options. The semen should be 
collected and frozen before the patient begins treatment for cancer, especially if the treatment 
involves chemotherapy or pelvic radiation. Testicular cancer is the most common malignancy 
in men of reproductive age (87). It is also the most common diagnosis which prompt men to 
cryopreserve their sperm. The prevalence of other diagnosis is outlined in Figure 4: 
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Figure 4. Types of cancer (%) in oncological patients who chose to cryopreserve semen. The 
“other cancers” category included bone sarcoma, thoracic cancer, and cancers of the prostate, 
mediastinum, mouth, brain, throat, lung, skin, and penis 
 
Reprinted from: Kobayashi H, Tamura K, Tai T, Nagao K, Nakajima K. Semen 
cryopreservation as an oncofertility treatment in 122 Japanese men with cancer: A decade‐long 
study. Reprod Med Biol. 2017;16:320–324. 
 
Semen for sperm cryopreservation is generally obtained by masturbation. It is the 
conventional, simplest, and most noninvasive method. However, at the time of diagnosis, many 
cancer patients are inpatients, of which some men might be already quite ill and unable to 
produce a sample. In these cases, surgical sperm retrieval can be offered. In postpubertal men, 
vibratory stimulation and/or electroejaculation (EEJ) may be an option. Unfortunately, 
electroejaculation for patients with normal sensory status requires general anesthesia. If the 
patient is too sick to undergo anesthesia, bedside sperm retrieval with local anesthesia may be 
considered, involving percutaneous epididymal sperm aspiration (PESA), needle testicular 
sperm extraction (TESE), or testicular sperm aspiration (TESA). The age of the patient and 
pubertal status are also potential dilemmas. Management of prepubertal men in brief may 
involve testicular biopsy or even orchiectomy for spermatogonia recovery, and finally 
cryopreservation followed by transplantation/stimulation. This is still experimental (88,89). 
After sperm retrieval, semen analyses are performed on all samples prior to cryopreservation. 
Semen parameters should be documented according to the WHO guideline. Sperm quality is 
defined by sperm count, sperm motility, and sperm morphology as well as freezability, for 
example the rate of post thaw viability of the semen. When semen is cryopreserved, a small 
subsample is frozen separately, thawed, and reanalyzed after the initial freeze. This test allows 
the post thaw survival to be determined as it can vary among individuals and even among 
different ejaculates from the same person. 
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The question of how many samples to freeze is determined by the sperm quality 
provided (90). This depends on the health of the patient and the type of cancer. It has been 
shown that the semen parameters of oncology patients before cancer treatment, both before 
freezing and after thawing, are worse than those of healthy donors (91,92). Hotaling et al. 
demonstrated that, prostate cancer had the best prefreeze total motile count (TMC) and 
lymphoid leukemia had the worst (92). Mean number of samples frozen is generally two. 
Sperm quality also depends on the abstinence period between semen collections. In a 
study involving cancer patients, Agarwal et al. showed that semen collection cryopreservation 
after 24 to ≤48 hours of abstinence is a sufficient time span to reach post-thaw quality 
comparable to that after an abstinence of 48 to ≤72 hours or longer (93). This is substantial for 
cancer patients who have to initiate antineoplastic therapy as soon as possible, and beforehand 
leaving the best manageable quality of semen sample to cryopreserve. 
Nevertheless, with IVF and ICSI, even the poorest samples are suitable to be frozen with 
high success rates. In a study of Meseguer et al. out of 186 cancer patients who banked sperm 
samples, approximately 15% actually made use of assisted reproduction technology (ART), 
resulting in 16 pregnancies (94).  
Finally, it is important to mention again that samples should be obtained and frozen 
before initiation of gonadotoxic therapy. In patients who have already been treated with 
antineoplastic measures, or patients who regain spermatogenesis after therapy, there is a high 
risk of sperm production that is genetically or structurally affected (94). 
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2. OBJECTIVE 
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The objective of this study is to outline the various advances that have been made in 
oncofertility, as well as its current weak points. It should highlight the still existing gender 
disparity and the problem of availability of certain techniques, like ovarian tissue freezing. The 
study also discloses the prevalence of cancer patients who need and want to undergo 
oncofertility procedures in Split. Furthermore, it should raise awareness and inform physicians 
as well as patients about the numerous possibilities of FP in patients diagnosed with cancer. 
Finally, the study points out the positive impact of this new emerging and important field of 
medicine on cancer survivors’ quality of life. 
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3. MATERIALS AND METHODS 
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3.1. Study design  
This retrospective case-control study was conducted in the Department of Obstetrics 
and Gynecology of the University Hospital Split of the University of Split, School of Medicine. 
The data stems from a time frame of 5 years, 2013 to 2018 respectively. 
 
3.2. Study Population 
In this study 72 patients were included, 66 men who cryopreserved sperm and 6 women 
who cryopreserved oocytes or embryos. All patients made use of FP techniques because of a 
cancer diagnosis. Exclusion criteria was any other motive for cryopreservation. Eligible patients 
were identified using data from the files of the Obstetrics and Gynecology Department at the 
University Hospital of Split. 
 
3.3. Materials 
Medical data of eligible patients was retrieved from the Reproductive Medicine 
laboratory at the University Hospital Split. Following laboratory data was collected for each 
patient, if available: 
1. Gender  
2. Year of birth  
3. Year in which cryopreservation took place  
4. Clinical condition of the patient which motivated him/her to preserve fertility 
 
 
3.4. Statistical Evaluation 
All collected data were gathered in a Microsoft Office Excel sheet. Data analysis was 
conducted using the statistical software STATISTICA 12. In this study data has been 
reproduced in the form of tables, graphs and methods of descriptive statistics. The difference in 
count between men and women was calculated with the Chi-Square test and a linear trend 
analysis was customized. The significance level was determined to be p < 0,001. 
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 In this study we collected data of 72 patients with cancer who underwent ART 
procedures in our department (Figure 5). 
 
 
Figure 5. Gender of patients  
This figure depicts the distribution of gender in our study population. While 92,5% of 
patients are male, only 7,5% are female (Chi square value 50,00; df=1; p<0,001). 
The average age is 30 years with a standard deviation of ± 5,7. The variation of the 
average value is 18,99%, as calculated in table 1. This data shows that most of the patients using 
cryopreservation are young patients in their reproductive age. 
 
Table 1. Descriptive Statistics 
  N Mean Median Q1 Q3 Std. dev. ± Coef.var. (%) 
Years of old 72 30.04 31 26 35 5,70 18,99 
 
  
Graph 1: Gender of patients 
 
Sex
female; 6; 8%
male; 66; 92%
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When analyzing the age distribution in Figure 2, the analysis shows that most patients 
in both groups (male and female) are 30 to 34 years old.  
 
 
Figure 6. Distribution of patients by age and gender 
 
 
Table 2. Type of cancer by gender 
  Sex - male % Sex - female % Row - Totals 
Testicular cancer 56 84.6% 0 0.0% 53 
Breast cancer 0 0.0% 5 83.3% 5 
Hodgkin Lymphoma 3 4.6% 0 0.0% 3 
Sarcoma 2 3.0% 0 0.0% 2 
Non Hodgkin Lymphoma 1 1.5% 0 0.0% 1 
Acute Leukemia 1 1.5% 0 0.0% 1 
Medulloblastoma 0 0.0% 1 16.7% 1 
Colon cancer 1 1.5% 0 0.0% 1 
Brain Tumor 1 1.5% 0 0.0% 1 
Anal cancer 1 1.5% 0 0.0% 1 
Totals 66 100.0% 6 100.0% 72 
 
Most male patients undergoing ART have testicular cancer. Out of 66 patients included 
in the study, 56 present with this type of cancer. Most female patients have breast cancer. Out 
of our 6 female patients, 5 were diagnosed with this type of cancer. 
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Table 3. Patients with cancer undergoing FP procedures from 2013 to 2018 
Cancer patients by years 
Year N % 
2013 14 19.44 
2014 10 13.89 
2015 6 8.33 
2016 21 29.17 
2017 20 27.78 
2018 1 1.39 
Total 72 100.00 
 
Table 3 demonstrates that in 2016 and 2017 more patients underwent ART procedures than in 
the 3 years before. The number climbed from 14 patients in 2013 to 20 patients in 2017. 
 
 
Figure 7. Patients’ prevalence by year 
Figure 7 points out how many cancer patients were treated for FP reasons in our 
department each year in the last 5 years. In 2013, 14 patients have been treated and in 2017 
there have been 20 patients. 
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Table 4. Assumption of patients with cancer from 2013 to 2022 
Time Number of patients 
2013 14 
2014 10 
2015 6 
2016 21 
2017 20 
2018 21* 
2019 23* 
2020 26* 
2021 28* 
2022 30* 
*expected value by linear trend model 
 
Table 4 illustrates the expectation of cancer patients undergoing ART procedures in the 
future, using a linear trend model. Calculated on basis of the patient count during the last 5 
years, in 2022 we would expect to have around 30 patients. 
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In the past decade, the concept of oncofertility for cancer patients has been rapidly 
evolving. This has been the result of increased post-cancer survival worldwide and the great 
impact of fertility preservation (FP) on the quality of life of cancer survivors (95). Currently, 
however, as our study has proven, there is only a small number of young cancer patients who 
receives fertility preservation services. This owes to a range of factors. First, it was only 
possible to include a small study population, limited to the patients of the University Hospital 
of Split and our study can therefore not represent numbers globally. Data about the actual 
disease of patients was sometimes missing in the documents, so not all potential participants 
could be included. Also, certain techniques, like ovarian tissue banking, are not yet available in 
our hospital and patients undergoing those interventions are not taken into account. Generally 
speaking, number one reason for the restrained usage of FP in Split as well as internationally, 
seems to be a universal lack of knowledge. Both physicians and patients are not well informed 
about available procedures in reproductive medicine. Early referral by oncologists before 
initiation of chemotherapy and radiotherapy is an important step for success in fertility 
preservation strategies. Unfortunately, it has been shown that a lot of oncologists fail to counsel 
their patients adequately. However, oncofertility not only includes oncology and reproductive 
medicine but several other disciplines such as gynecology, urology, internal medicine, 
pediatrics, psychology and bioethics. It is therefore necessary to promote further education and 
continuous training in all these fields, to ensure the best cooperation and results in this 
upcoming branch.  
Health networks are essential to improve coordination of care, and the strengthening of 
this coordination is a major challenge to improve the performance of the health system. 
Throughout the past 10 years, numerous international guidelines were published concerning 
anticancer treatments and fertility preservation. Such important guidelines were published by 
American Society of Clinical Oncology (ASCO), American Society for Reproductive Medicine 
(ASRM), European Society for Medical Oncology (ESMO), American Oncofertility 
Consortium (OC), International Society for Fertility Preservation (ISFP), Fertility Preservation 
Network FertiPROTEKT, American Academy of Pediatrics (AAP), and Association of 
Pediatric Hematology/Oncology Nurses (APHON) (96). 
Nowadays embryo and oocyte cryopreservation are considered the golden standard for 
female cancer patients, and sperm cryopreservation for male cancer patients. A new and 
promising approach for females, especially prepubertal patients, is ovarian tissue freezing. 
While embryo CP is the first and most widely used option in the world, ovarian tissue banking 
is not universally available. Currently there are only a few medical centers with international 
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experience in performing ovarian tissue banking: about 100 worldwide and including 23 in 
France (95). Unfortunately, it is not yet available in Split. 
Another issue in oncofertility seems to be the inequality in access between men and 
women. In our study 66 men made use of sperm banking while only 6 women underwent 
embryo or oocyte CP. This certainly owes to the fact that ART in women demands a far more 
complicated and time-consuming procedure, including COS and finally harvesting oocytes via 
transvaginal ultrasound. This is a painful procedure which might even require sedation or 
anesthesia. Moreover, women might not be aware of the potential fertility loss, while still being 
shocked by their diagnosis, and might also fear to delay cancer treatment or the procedure of 
ART itself. It has been reported that adequate counseling and assisted decision-making improve 
the number of women who choose to undergo fertility preservation treatments (97).  
Our study suggests an incentive upward trend of FP methods. Excluding the data for 
2018, which are not representative as they do not incorporate all patients who underwent or are 
still undergoing procedures and taking into consideration that our laboratory was only working 
for 2 months in 2015, we can see a slight but steady rise in the number of patients during the 
last 5 years. This also reflects in our linear trend analysis, which states that in 2022, 30 patients 
(16 more patients than in 2013) with cancer may be treated for FP reasons in our department in 
the University Hospital of Split. 
Although the number of the patients who receive fertility preservation services has been 
increasing, another major factor, concerning female as well as male patients, is certainly the 
severe physical and emotional stress after cancer diagnosis. Having to make a decision with 
limited time, while still coming to terms with a potentially life-threatening diagnosis, can cause 
patients to feel overwhelmed. A poor-quality fertility discussion and inadequate information 
may add to this feeling of uneasiness (98). A survey on adult and pediatric oncology providers 
in the USA showed that the majority felt discomfort while discussing on fertility preservation, 
partly because of the lack of knowledge about options or places to refer, and that this discomfort 
hindered final referrals to specialists (99). It is therefore essential to inform all cancer patients 
thoroughly about current techniques and available medical centers, and to integrate them into 
systematic long-term follow-up. Lack of time and lack of knowledge are identified as the main 
barriers to the initiation of FP discussion and the training of healthcare providers remains a 
challenge until this day. It is crucial to further promote education in oncofertility measures in 
order to yield a higher number of patients undergoing procedures in the future.  
However, it should be noted that the still limited use of these procedures may be due 
also to their high costs (100). A study of Katz et al. has shown that in America median per-
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person costs ranged from $1,182 for medications only, to $24,373 and $38,015 for IVF. Within 
the timeframe of the study, costs were not significantly different for women who were 
successful in achieving pregnancy and women who were not (101). This puts an additional 
financial burden on cancer patient. First of all, it is not sure that ART procedures will be 
successful, second of all patients face an unsafe future being diagnosed with cancer. 
Undergoing such expensive treatment carries the risk of not paying off in the end. 
Another potential hazard is the topic of FP in pediatric patients. Pivotal differences in 
the FP procedures offered to children and adults may affect the decision. In adults, the 
procedures available have proven efficacy and are less invasive. However, gonadal tissue 
cryopreservation in children is invasive, experimental, and carries a risk of reimplantation of 
cancerous cells. Although FP using established techniques may have positive outcomes and 
increase satisfaction in adults, this may not translate to the experiences of young children. 
Furthermore, the overwhelming feeling commonly reported among adult cancer patients 
making FP decisions, may be more extreme for parents, as they decide not for themselves but 
their child and as there is no guarantee of success (98). 
In pediatric patients as well as in adults, there is still a lot of room and need for new 
techniques and procedures to best preserve fertility in the future. Several novel approaches are 
under development for fertility preservation in women and men. In vitro growth and maturation 
of follicles is a promising technique for female patients. Immature follicles, such as secondary, 
primary, or even primordial follicles, are harvested from ovarian tissue and cultured in vitro to 
produce mature oocytes (102). This technique would have the advantage of overcoming the risk 
of MRD following ovarian tissue cryopreservation. Another approach which has been 
successful in rodents, would be generating germ cells in vitro from pluripotent stem cells, 
although many technical and ethical issues need to be addressed for humans. New strategies for 
gonadal protection are also under investigation (103). One is the drug delivery system (DDS) 
to enhance the site selectivity and reduce the exposure of ovary, a nontargeted organ, to 
anticancer agents. The other is to administer the agents which reduce gonadal damage. For 
prepubertal male patients, testicular tissue cryopreservation is the method of choice to preserve 
fertility and offer reproductive options later on. In young boys however, testicular tissue 
contains sperm stem cells (SSC) but may not yet contain mature spermatozoa. Mature 
spermatozoa are the only cells though that can be used for contemporary fertility techniques. 
Future techniques include in vitro maturation of SSC into mature sperm cells for subsequent 
use in IVF/ICSI, or germ-cell transplant into native testicular tissue to allow fertility restoration. 
These techniques have been performed successfully in animal models but never in humans 
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(104). Maturation of SSC followed by IVF/ICSI has been shown to work remarkably well in 
mouse models in a study of Sato et al. in 2013, and the full differentiation of human SSC into 
mature sperm cells in vitro was recently demonstrated by Zhou et al. in 2016 (105,106). 
However, IVF/ICSI using human mature sperm cells derived from SSC in vitro has not been 
shown. Autologous testicular cell transplantation is an exciting potential option that has been 
used successfully with many animal models since 1994 (107). In 2012, a study of Herman et 
al. demonstrated the feasibility of testicular cell transplantation for restoring fertility in Rhesus 
macaque after undergoing bone marrow transplantation (108). Transplanting germ cells back 
into the gonads of a human patient after anticancer therapy to restore fertility potential has not 
yet been attempted. Among many technical challenges remaining is the task of purifying SSC 
populations effectively so that no malignant cells are reintroduced in the process. 
Physicians as well as patients being not well acquainted with the subject of oncofertility, 
high costs, lack of knowledge and high-quality counseling, lack of sufficient long-term data on 
specific methods in humans, lack of reproductive medical centers worldwide and certainly also 
the lack of currently available procedures, result in many cancer patients not choosing to 
undergo fertility preservation. Hence, as endorsed by major international guidelines, it is crucial 
to promote the branch of oncofertility internationally, to provide services to the patients 
worldwide. Furthermore, we must improve the knowledge by long term follow-up of cancer 
patients undergoing ART and reduce costs to make the procedures more available for everyone 
in need. The final goal should be to counsel all cancer patients about the treatment-related loss 
of fertility and to assist them in taking decisions on fertility preservation to ensure their best 
quality of life after antineoplastic therapy. 
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1. Until this day, there is an uneven distribution in gender concerning the use of fertility 
preservation measures. While 92,5% of patients are male, only 7,5% are female. This stems 
from a combination of lack of knowledge concerning available procedures in women, high 
costs and the fear of the intervention itself. 
2. The average age for cancer patients undergoing fertility preservation procedures is 30 to 34 
years. This shows that most of the patients using cryopreservation are young patients in 
their reproductive age. 
3. A majority of male patients undergoing ART have testicular cancer. Out of 66 patients 
included in the study, 56 were diagnosed with this type of cancer. Most female patients have 
breast cancer, meaning 5 female patients respectively. 
4. If we consider the usage of ART during the last 5 years, we can expect an upward trend in 
the future, where more and more cancer patients will undergo interventions to secure their 
fertility.  
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Objectives: The objective of this study is to raise awareness and inform physicians as well as 
patients about the numerous different possibilities of fertility preservation in patients diagnosed 
with cancer. It should highlight the still existing gender disparity and the problem of availability 
of certain techniques, like ovarian tissue freezing. The study also discloses the prevalence of 
cancer patients who need and want to undergo oncofertility procedures in Split. 
 
Materials and Methods: In this study 72 patients were included, 66 men who cryopreserved 
sperm and 6 women who cryopreserved oocytes or embryos in the University Hospital of Split. 
All patients made use of fertility preservation techniques because of a cancer diagnosis. Data 
was collected from patients’ files of the Department of Gynecological Endocrinology and 
Human Reproduction from the last 5 years. 
 
Results: In our study 92,5% of patients are male, and only 7,5% are female (Chi square value 
50,00; df=1; p<0,001). This clearly outlines the predominance of male (66) over female (6) 
patients. The average age is 30 years with a standard deviation of ± 5,7. The variation of the 
average value is 18,99%. When analyzing the age distribution, the analysis shows that most 
patients, male and female, are 30 to 34 years old. Most male patients undergoing ART have 
testicular cancer. Out of 66 patients included in the study, 56 present with this type of cancer. 
Most female patients have breast cancer. Out of our 6 female patients, 5 were diagnosed with 
this type of cancer. 
 
Conclusion: For oncofertility to function and achieve the best possible results, it is necessary 
to properly educate all physicians involved in the care of the patients. The availability of 
procedures needs to be improved internationally. More women diagnosed with cancer should 
be able to have recourse to fertility preservation. It is of great significance to further invest in 
this branch of medicine in order to improve safety and physician’s performance on existing 
methods, as well as revealing new procedures. 
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Naslov: Onkofertilitetni postupci Zavoda za ginekološku endokrinologiju i humanu 
reprodukciju, Klinički bolnički centar Split  
Cilj: Cilj ovog istraživanja je povećati svijest i informirati liječnika i pacijente o brojnim 
mogućnostima očuvanja plodnosti kod oboljelih od malignoma. Valja istaknuti i dalje postojeće 
rodne nejednakosti i problem dostupnosti određenih tehnika, kao što je zamrzavanje tkiva 
jajnika. Studija također otkriva učestalost bolesnika s karcinomom koji trebaju i žele proći 
oncofertility postupke u Splitu. 
Materijali i metode: U ovu studiju su uključena 72 pacijenta, 66 muškaraca koji su 
kriopohranili svoje sjeme i 6 žena koje su kriopohranile svoje zametke ili jajne stanice. Svi su 
to učinili zbog maligne bolesti a u smislu očuvanja kasnije plodnosti. Podaci su prikupljeni od 
pacijenata datoteke Odjela za ginekologiju endokrinologiju i humanu reprodukciju od zadnjih 
5 godina. 
Rezultati: U našem istraživanju 92,5% pacijenata su bili muškarci i samo 7,5% su bile žene ( 
Hi-kvadrat test 50,00 df=1 p<0,001). Navedeno pokazuje izrazitu predominaciju muških nad 
ženskim pacijentima. Prosječna dob ispitanika je 30 godina sa standardnom devijacijom ±5,7. 
Varijacija prosječne vrijednosti je 18,89%. Analiza dobne distribucije pokazala je da je većina 
i muških i ženskih pacijenata između 30-34 godine starosti. Većina muškaraca koji su 
kriopohranili svoje sjeme bolovala je od tumora testisa. Od njih 66 uključenih u istraživanje 
čak njih 56 imalo je tumor testisa. Većina žena bolovala je od tumora dojke. Od njih 6 
uključenih u studiju, pet ih je imalotumor dojke. 
Zaključak: Za onkofertilitetne postupke da bi funkionirali i postigli što bolje rezultate 
neophodno je adekvatno educirati sve liječnike uključene u rad s ovimpacijentima. Dostupnost 
postupaka treba poboljšati na međunarodnoj razini. Više žena dijagnosticiran rak bi trebao biti 
u mogućnosti obratiti se očuvanje plodnosti. Od velikog značaja za daljnji razvoj ove grane je 
povećati sigurnost za pacijente te uspješnost postojećih metoda uz razvoj novih onkofertilitetnih 
postupaka. 
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